tiprankstipranks
Advertisement
Advertisement

RAPP Stock Latest News

Rapport Therapeutics initiated with an Outperform at Leerink
The FlyRapport Therapeutics initiated with an Outperform at Leerink
17d ago
RAPP
Rapport Therapeutics management to meet with Citizens
PremiumThe Fly
Rapport Therapeutics management to meet with Citizens
24d ago
RAPP
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting
PremiumCompany Announcements
Rapport Therapeutics Holds 2026 Annual Shareholder Meeting
1M ago
8K
RAPP
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy
PremiumCompany Announcements
RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy
1M ago
RAPP
Rapport Therapeutics price target raised to $65 from $53 at BTIG
PremiumThe Fly
Rapport Therapeutics price target raised to $65 from $53 at BTIG
2M ago
RAPP
Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
PremiumRatingsAnalyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside
2M ago
RAPP
Rapport Therapeutics assumed with a Buy at Truist
Premium
The Fly
Rapport Therapeutics assumed with a Buy at Truist
2M ago
RAPP
Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile
Premium
Ratings
Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile
2M ago
RAPP
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market
PremiumCompany Announcements
Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market
2M ago
RAPP
Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)
PremiumThe Fly
Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)
2M ago
RAPP
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
PremiumCompany Announcements
Rapport Therapeutics advances RAP-219 after strong Phase 2a data
3M ago
8K
RAPP
Rapport Therapeutics presents results from Phase 2a trial of RAP-219
PremiumThe Fly
Rapport Therapeutics presents results from Phase 2a trial of RAP-219
3M ago
RAPP
Rapport Therapeutics initiated with a Strong Buy at Raymond James
PremiumThe FlyRapport Therapeutics initiated with a Strong Buy at Raymond James
3M ago
RAPP
Closing Bell Movers: Markets on edge ahead of US-Iran talks
Premium
The Fly
Closing Bell Movers: Markets on edge ahead of US-Iran talks
3M ago
FGI
SLP
Rapport Therapeutics initiated with a Strong Buy at Raymond James
Premium
The Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
3M ago
RAPP
Rapport Therapeutics initiated with a Strong Buy at Raymond James
PremiumThe Fly
Rapport Therapeutics initiated with a Strong Buy at Raymond James
3M ago
RAPP
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
PremiumRatings
Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
4M ago
RAPP
Rapport Therapeutics files automatic mixed securities shelf
PremiumThe Fly
Rapport Therapeutics files automatic mixed securities shelf
4M ago
RAPP
Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)
PremiumThe Fly
Rapport Therapeutics reports Q4 EPS (72c), consensus (67c)
4M ago
RAPP
Rapport Therapeutics sees cash runway into 2H29
PremiumThe FlyRapport Therapeutics sees cash runway into 2H29
4M ago
RAPP
Rapport, Tenacia announce collaboration for RAP-219 in Greater China
Premium
The Fly
Rapport, Tenacia announce collaboration for RAP-219 in Greater China
4M ago
RAPP
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
Premium
Company Announcements
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next
5M ago
RAPP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >